• Adverse Events and Oncotargeted Kinase Inhibitors (Hardback) 9780128094006
1 1
£119.97 GBP
£157.00 GBP £119.97 GBP
Sale Sold out
Free UK Shipping

Freshly Printed - allow 10 days lead

Adverse Events and Oncotargeted Kinase Inhibitors

Systematically examines safety profiles from numerous sources to inform the latest adverse events associated with a growing class of anti-tumor drugs

Giuseppe Tridente (Author)

9780128094006

Hardback, published 8 May 2017

736 pages
27.6 x 21.5 x 3.8 cm, 2.22 kg

Approx.716 pages

Part I: General Aspects1. Introduction2. Protein and Lipid Kinases3. Kinase Inhibitors4. Adverse Events

Part II: Oncotargeted Kinase Inhibitors5. Imatinib6. Gefitinib7. Erlotinib8. Sorafenib9. Sunitinib10. Dasatinib11. Lapatinib12. Nilotinib13. Pazopanib14. Vandetanib15. Vemurafenib16. Crizotinib17. Ruxolitinib18. Axitinib19. Bosutinib20. Regorafenib21. Cabozantinib22. Ponatinib23. Dabrafenib24. Trametinib25. Adatinib26. Idelalisib27. Ibrutinib

Part III: Overview28. Kinase Inhibitors as Adverse Event Inducers29. Kinase Inhibitors as Drug Class Events30. Conclusion and Perspectives

Subject Areas: Pharmacology [MMG]
View full details